doi:10.3969/j.issn.1673-8640.2018.07.013

Abstract

CLC Number:

R446.1

Figures/Tables 3

References 12

[1]	FISMAN D N.Syphilis resurgent in China[J] . Lancet,2007,369(9556):84-85.
[2]	NORRIS S J.Polypeptides of Treponema pallidum: progress toward understanding their structural, functional, and immunologic roles. Treponema Pallidum Polypeptied Research Group[J]. Microbiol Rev,1993,57(3):750-779.
[3]	DE LEMOS E A,BELÉM Z R,SANTOS A,et al. Characterization of the Western blotting IgG reactivity patterns in the clinical phases of acquired syphilis[J]. Diagn Microbiol Infect Dis,2007,58(2):177-183.
[4]	PARK B G,YOON J G,RIM J H,et al.Comparison of six automated Treponema-specific antibody assays[J]. J Clin Microbiol,2016,54(1):163-167.
[5]	SOMMESE L,SABIA C,ESPOSITO A,et al.Comparison of performance of two Treponema pallidum automated chemiluminescent immunoassays in blood donors[J]. Infect Dis(Lond), 2016,48(6):483-487.
[6]	Centers for Disease Control and Prevention (CDC). Discordant results from reverse sequence syphilis screening-five laboratories,United States,2006-2010[J]. MMWR Morb Mortal Wkly Rep,2011,60(5):133-137.
[7]	Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines,2015 [EB/OL]. (2015-06-05)[2018-03-15]. .
[8]	HOOVER K W,RADOLF J D.Serodiagnosis of syphilis in the recombinant era:reversal of fortune[J]. J Infect Dis,2011,204(9):1295-1296.
[9]	BAKER-ZANDER S A,HOOK E W 3rd,BONIN P,et al. Antigens of Treponema pallidum recognized by IgG and IgM antibodies during syphilis in humans[J]. J Infect Dis,1985,151(2):264-272.
[10]	United Nations Development Programme, World Bank,World Health Organization,et al. Laboratory-based evaluation of rapid syphilis diagnostics[R]. Geneva:WHO,2003.
[11]	SIEDNER M,ZAPITZ V,ISHIDA M,et al.Performance of rapid syphilis tests in venous and fingerstick whole blood specimens[J]. Sex Transm Dis,2004,31(9):557-560.
[12]	SEÑA A C,WHITE B L,SPARLING P F. Novel Treponema pallidum serologic tests:a paradigm shift in syphilis screening for the 21st century[J]. Clin Infect Dis,2010,51(6):700-708.

组别	例数	免疫层析法		CMIA
组别	例数	有反应性	无反应性	有反应性	无反应性
第1组	125	122	3	125	0
第2组	25	23	2	25	0
第3组	200	8	192	16	184

组别	例数	免疫层析法		CMIA
组别	例数	有反应性	无反应性	有反应性	无反应性
第1组	125	122	3	125	0
第2组	25	23	2	25	0
第3组	200	8	192	16	184

样本号		TPPA		TRUST	免疫层析法	CMIA	免疫印迹法
样本号		TPPA		TRUST	免疫层析法	CMIA	TpN15	TpN17	TpN45	TpN47	报告
1		阳性1∶80+		-	-	+	-	+	-	+/-	+
2		阳性1∶80+		-	-	+	-	+/-	-	+	+
3		阳性1∶80++		-	-	+	-	+	-	+/-	+
4		1∶80+/-		-	-	+	-	-	+	+	+
5		1∶80+/-		-	-	+	+	+/-	+/-	+/-	+
6		-		-	+/-	+	-	-	-	+	临界
7		-		-	+/-	+	-	+	+	-	+
8		-		-	+/-	-	-	-	-	-	-
9		-		-	+/-	-	-	-	+	-	临界
10		-		-	+/-	+	-	+	-	+/-	+
11		-		-	+/-	+	-	-	-	-	-
样本号	TPPA		TRUST	免疫层析法	CMIA	免疫印迹法
样本号	TPPA		TRUST	免疫层析法	CMIA	TpN15	TpN17	TpN45	TpN47	报告
12	-		-	+/-	-	-	-	-	+/-	临界
13	-		-	+/-	+	-	-	-	+/-	临界
14			-	-	+	-	+	-	-	临界
15	-		-	-	+	-	-	-	-	-
16	-		-	-	+	-	+	-	-	临界
17	-		-	-	+	+/-	-	+/-	-	+
18	-		-	-	+	+	-	-	-	临界
19	-		-	-	+	-	-	-	-	-
20	-		-	-	+	-	+	-	-	临界
21	-		-	-	+	-	+	+/-	-	+
22	-		-	-	+	-	-	-	-	-
23	-		-	-	+	-	+	+	-	+
24	-		-	-	+	-	-	-	-	-

样本号		TPPA		TRUST	免疫层析法	CMIA	免疫印迹法
样本号		TPPA		TRUST	免疫层析法	CMIA	TpN15	TpN17	TpN45	TpN47	报告
1		阳性1∶80+		-	-	+	-	+	-	+/-	+
2		阳性1∶80+		-	-	+	-	+/-	-	+	+
3		阳性1∶80++		-	-	+	-	+	-	+/-	+
4		1∶80+/-		-	-	+	-	-	+	+	+
5		1∶80+/-		-	-	+	+	+/-	+/-	+/-	+
6		-		-	+/-	+	-	-	-	+	临界
7		-		-	+/-	+	-	+	+	-	+
8		-		-	+/-	-	-	-	-	-	-
9		-		-	+/-	-	-	-	+	-	临界
10		-		-	+/-	+	-	+	-	+/-	+
11		-		-	+/-	+	-	-	-	-	-
样本号	TPPA		TRUST	免疫层析法	CMIA	免疫印迹法
样本号	TPPA		TRUST	免疫层析法	CMIA	TpN15	TpN17	TpN45	TpN47	报告
12	-		-	+/-	-	-	-	-	+/-	临界
13	-		-	+/-	+	-	-	-	+/-	临界
14			-	-	+	-	+	-	-	临界
15	-		-	-	+	-	-	-	-	-
16	-		-	-	+	-	+	-	-	临界
17	-		-	-	+	+/-	-	+/-	-	+
18	-		-	-	+	+	-	-	-	临界
19	-		-	-	+	-	-	-	-	-
20	-		-	-	+	-	+	-	-	临界
21	-		-	-	+	-	+	+/-	-	+
22	-		-	-	+	-	-	-	-	-
23	-		-	-	+	-	+	+	-	+
24	-		-	-	+	-	-	-	-	-

方法	免疫印迹法			总计^*
方法	+	-	临界	总计^*
免疫层析法	7	2	4	13
CMIA	5	5	6	16

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 3

References 12

Related Articles 15

Recommended Articles

Metrics

[1]	GAO Zikang, CHEN Jing. Construction of a nomogram prediction model for the prognosis of patients with depressive disorder based on the characteristics of peripheral blood lymphocyte subsets [J]. Laboratory Medicine, 2025, 40(12): 1146-1152.
[2]	WANG Tian, ZHANG Yun, BAI Yi, ZHAI Weibin, ZHAO Hai. Roles of PIV，SII and NPAR in the diagnosis of spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites [J]. Laboratory Medicine, 2025, 40(12): 1153-1158.
[3]	HUANG Ting, XU Yan, SHI Qingxing, PENG Ying. Roles of miR-944 and MARCH7 mRNA in prognosis assessment of non-small cell lung cancer patients [J]. Laboratory Medicine, 2025, 40(12): 1159-1164.
[4]	LI Minghong, MIN Cuili, GUO Qingbo, MA Lujuan. Predictive roles of serum 25（OH）D and SAA for the response to immunosuppressive therapy in autoimmune hepatitis [J]. Laboratory Medicine, 2025, 40(12): 1165-1170.
[5]	ZHEN Di, JIA Bin, MENG Xianyi. Roles of serum sPD-1 and sTWEAK levels in patients with ulcerative colitis in disease monitoring and prognosis assessment [J]. Laboratory Medicine, 2025, 40(12): 1171-1176.
[6]	ZHAO Yilin, XU Yan, YIN Hui. Roles of serum miR-145-5p，miR-200C-3p and miR-1290 in prognosis assessment of patients with papillary thyroid carcinoma [J]. Laboratory Medicine, 2025, 40(12): 1177-1182.
[7]	LI Song, XIANG Xu. Risk factors for poor prognosis in elderly patients with severe fever and thrombocytopenia syndrome and their clinical significance [J]. Laboratory Medicine, 2025, 40(12): 1183-1189.
[8]	CHANG Nan, WEI Yali, LU Qifeng, LI Tian, HOU Tingting, LI Yuan, ZHU Mengyu, SHEN Yajuan. A machine learning early warning model for acute promyelocytic leukemia based on blood cell analyzer parameters [J]. Laboratory Medicine, 2025, 40(12): 1190-1196.
[9]	. [J]. Laboratory Medicine, 2025, 40(12): 1197-1202.
[10]	. [J]. Laboratory Medicine, 2025, 40(12): 1216-1221.
[11]	. [J]. Laboratory Medicine, 2025, 40(12): 1222-1226.
[12]	BAO Wen. Application and prospect of microsatellite instability determination in tumor diagnosis and treatment [J]. Laboratory Medicine, 2025, 40(12): 1227-1231.
[13]	XIONG Ying, GUO Wei. From generic to personalized：the evolution and frontiers of indirect methods for establishing reference interval [J]. Laboratory Medicine, 2025, 40(11): 1035-1041.
[14]	CHEN Yanqin, FAN Lina, YANG Dagan. Six indirect method algorithms for establishing the reference range of serum cystatin C for adults in Hangzhou and consistency analysis [J]. Laboratory Medicine, 2025, 40(11): 1047-1052.
[15]	LIU Chunyan, NIU Shumin, DENG Zhaohui, LIANG Mengjie, ZHANG Xin. Establishing the reference ranges for AFP，CEA，CA72-4 and CA19-9 in Urumqi region by indirect method [J]. Laboratory Medicine, 2025, 40(11): 1053-1058.